Table 4 Five Year Disease Free and Overall Survival.

Whole Cohort

3453

88.1% (86.96–89.31)

94.1% (93.25–94.98)

<2 cm

670

91.1% (88.77–93.45)

96.9% (95.47–98.38)

2.1–3 cm

1323

90.3% (88.61–92.1)

95.5% (94.22–96.7)

3.1–5 cm

1037

85.9% (83.61–88.25)

92.4% (90.63–94.2)

>5.1 cm

239

80.9% (75.74–86.45)

87.4% (82.89–92.2)

Node Negative

1788

92% (90.64–93.39)

96.2% (95.2–97.15)

Node Positive

1645

83.9% (82.03–85.89)

91.8% (90.36–93.31)

ER/PR + / HER2−

1751

91.6% (90.19–93.02)

96.1% (95.12–97.1)

ER/PR Any/ HER2 +

654

81.3% (78.11–84.61)

90.6% (88.17–93.15)

Triple Negative

769

85.5% (82.79–88.22)

92.7% (90.73–94.8)

ER/PR +/ HER2−/ Node +

861

88.7% (86.39–91.01)

94.4% (92.72–96.11)

ER/PR +/ HER2−/ Node −

882

94.4% (92.8–96.1)

97.7% (96.63–98.75)

ER/PR Any/ HER2 +/Node +

358

75.9% (71.22–80.81)

87.3% (83.45–91.28)

ER/PR Any/ HER2 +/ Node −

295

87.9% (83.95–92.11)

94.4% (91.65–97.32)

Triple Negative/ Node +

294

79.5% (74.61–84.66)

90.1% (86.42–93.98)

Triple Negative/ Node −

472

89.6% (86.62–92.64)

94.6% (92.31–96.87)

<2 cm/Node +

251

86.8% (82.48–91.34)

96.2% (93.64–98.83)

<2 cm/Node −

415

93.9% (91.38–96.49)

97.7% (96.05–99.29)

2.1–3 cm/Node +

596

87.5% (84.65–90.5)

94.3% (92.21–96.35)

2.1–3 cm/Node −

726

92.5% (90.48–94.66)

96.4% (94.88–97.88)

3.1–5 cm/Node +

568

81.6% (78.15–85.13)

89.6% (86.79–92.42)

3.1–5 cm/Node −

465

91% (88.26–93.95)

95.7% (93.76–97.74)

>5.1 cm/Node +

142

75.1% (67.81–83.14)

83.4% (76.75–90.58)

>5.1 cm/Node −

97

89.4% (83–96.21)

93% (87.73–98.59)

ER/PR +/HER2−

238

97.5% (95.3–99.7)

99.1% (97.79–100)

ER/PR Any/HER2+

68

88.9% (80.72–97.82)

100% (100–100)

Triple Negative

71

86.5% (78.27–95.68)

92.8% (86.25–99.89)